IL286283A - Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics - Google Patents

Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics

Info

Publication number
IL286283A
IL286283A IL286283A IL28628321A IL286283A IL 286283 A IL286283 A IL 286283A IL 286283 A IL286283 A IL 286283A IL 28628321 A IL28628321 A IL 28628321A IL 286283 A IL286283 A IL 286283A
Authority
IL
Israel
Prior art keywords
pah
viral dna
dna vectors
phenylalanine hydroxylase
therapeutic expression
Prior art date
Application number
IL286283A
Other languages
English (en)
Hebrew (he)
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of IL286283A publication Critical patent/IL286283A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16001—Phenylalanine 4-monooxygenase (1.14.16.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL286283A 2019-03-13 2021-09-12 Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics IL286283A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962817771P 2019-03-13 2019-03-13
US201962857514P 2019-06-05 2019-06-05
PCT/US2020/022595 WO2020186150A2 (en) 2019-03-13 2020-03-13 Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics

Publications (1)

Publication Number Publication Date
IL286283A true IL286283A (en) 2021-10-31

Family

ID=72426457

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286283A IL286283A (en) 2019-03-13 2021-09-12 Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics

Country Status (12)

Country Link
US (1) US12415002B2 (cg-RX-API-DMAC7.html)
EP (1) EP3938515A4 (cg-RX-API-DMAC7.html)
JP (2) JP7583732B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210149702A (cg-RX-API-DMAC7.html)
CN (1) CN113874508A (cg-RX-API-DMAC7.html)
AU (1) AU2020235121A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017852A2 (cg-RX-API-DMAC7.html)
CA (1) CA3133330A1 (cg-RX-API-DMAC7.html)
IL (1) IL286283A (cg-RX-API-DMAC7.html)
MX (1) MX2021011037A (cg-RX-API-DMAC7.html)
SG (1) SG11202109830TA (cg-RX-API-DMAC7.html)
WO (1) WO2020186150A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021252952A1 (en) * 2020-06-11 2021-12-16 Sangamo Therapeutics, Inc. Methods and compositions for expressing phenylalanine hydroxylase
MX2023001109A (es) 2020-07-27 2023-04-24 Anjarium Biosciences Ag Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
MX2023003019A (es) * 2020-09-16 2023-05-08 Generation Bio Co Vectores de adn de extremo cerrado y usos de estos para expresar fenilalanina hidroxilasa (pah).
GB202014751D0 (en) * 2020-09-18 2020-11-04 Lightbio Ltd Targeting vector
KR20230079172A (ko) 2020-10-01 2023-06-05 젠자임 코포레이션 간-유도 유전자 대체 요법에 의한 pku의 치료를 위한 인간 pah 발현 카세트
CN115772503B (zh) * 2022-08-16 2023-10-17 广东省南山医药创新研究院 一种表达pah的基因修饰细胞药物及其制备方法与应用
CN121532216A (zh) * 2023-04-18 2026-02-13 赛仁生物技术公司 腺相关病毒载体组合物和使用方法
CN116656740A (zh) * 2023-05-30 2023-08-29 浙江大学 一种腺相关病毒基因治疗载体及其在制备治疗苯丙酮尿症的药物中的应用
CN119876192B (zh) * 2024-07-02 2025-11-07 浙江大学滨江研究院 用于治疗苯丙酮尿症的多核苷酸

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511373B (zh) * 2006-06-19 2015-12-09 阿斯克肋匹奥生物制药公司 用于基因治疗的修饰的因子ⅷ和因子ⅸ基因和载体
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
IL261524B2 (en) 2016-03-03 2023-10-01 Univ Massachusetts End-capped linear double-stranded DNA for non-viral gene transfer
EP3562494A4 (en) * 2016-12-30 2020-08-19 The Trustees Of The University Of Pennsylvania GENE THERAPY FOR THE TREATMENT OF PHENYLKETONURIS
WO2018167621A1 (en) * 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
US11820999B2 (en) * 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
EP3630200A4 (en) * 2017-05-31 2021-02-24 Arcturus Therapeutics, Inc. THERAPEUTICS FOR PHENYLKETONURIA
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.

Also Published As

Publication number Publication date
US12415002B2 (en) 2025-09-16
MX2021011037A (es) 2021-12-15
WO2020186150A3 (en) 2020-10-29
US20230024354A1 (en) 2023-01-26
CA3133330A1 (en) 2020-09-17
JP2025016685A (ja) 2025-02-04
JP7583732B2 (ja) 2024-11-14
BR112021017852A2 (pt) 2021-11-30
CN113874508A (zh) 2021-12-31
EP3938515A4 (en) 2022-12-28
SG11202109830TA (en) 2021-10-28
JP2022525302A (ja) 2022-05-12
WO2020186150A2 (en) 2020-09-17
AU2020235121A1 (en) 2021-11-04
KR20210149702A (ko) 2021-12-09
EP3938515A2 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
EP3458585A4 (en) GENE THERAPY PROCEDURES FOR AGE-RELATED ILLNESSES AND SUFFERING
IL285269A (en) Compositions and methods for treating neurocognitive disorders
EA202192815A1 (ru) Опосредуемая aav-вектором делеция крупной мутационной "горячей точки" для лечения мышечной дистрофии дюшенна
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
IL280636A (en) Alternative splicing regulation of gene expression and therapeutic methods
HRP20260212T1 (hr) Pripravci i postupci za liječenje mišićne distrofije
MA50096A (fr) Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux
IL285270A (en) Compositions and methods for treating neurocognitive disorders
EP3621648A4 (en) TRISPECIFIC PROTEINS MSLN AND METHOD OF USE
IL290792A (en) Compositions and methods for the treatment of viral infections
EA201891317A2 (ru) Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
IL282140A (en) Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
IL290132A (en) Materials and methods for treating friedreich's ataxia
EP3402885A4 (en) CHIMERIC PROTEINS AND METHOD FOR REGULATING GENE EXPRESSION
MA46290A (fr) Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
IL291192A (en) Compositions and methods of treating lupus nephritis
EP3938515A4 (en) NONVIRAL DNA VECTORS AND USES THEREOF FOR THE EXPRESSION OF PHENYLALANINE HYDROXYLASE (PAH) THERAPEUTICS
IL286811A (en) Compositions and methods for stabilizing protein-containing formulations
MA46111A (fr) Bactéries génétiquement modifiées sécrétant des protéines thérapeutiques et procédés d'utilisation de celles-ci
EP3762407A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER WITH ECM AFFINITY PEPTIDES BONDED TO CYTOKINE
IL292460A (en) Huntingtin (htt) irna agent compositions and methods of use thereof
EP3980067A4 (en) ANTIBODY INTERLEUKIN FUSION PROTEIN AND METHODS OF USE
EP3723739A4 (en) PARASITICIDAL ISOXAZOLINE FORMULATIONS AND METHODS OF TREATMENT OF BLEPHARITIS
IL290817A (en) Methods for production of human recombinant arginase 1 and uses thereof
IL281577A (en) Compositions and methods for treating retinitis pigmentosa